Moderna Reports 71% Enrollment in Coronavirus Vaccine Trial

Moderna (NASDAQ:MRNA) continues to make progress enrolling patients in the phase 3 clinical trial testing its coronavirus vaccine, mRNA-1273. In its weekly update, the biotech said 21,411 patients were enrolled in the study. With a target of approximately 30,000 participants, the 71% enrollment in the study is up substantially from last week, when the company reported enrollment of 17,458 participants, or 58% of the targeted enrollment.